Copper and anti-anhedonic effect of ketamine in treatment-resistant depression

Jakub Słupski; Wiesław Jerzy Cubała; Natalia Górska; Anita Słupska; Maria Gałuszko-Węgielnik

doi:10.1016/j.mehy.2020.110268

Copper and anti-anhedonic effect of ketamine in treatment-resistant depression

Med Hypotheses. 2020 Nov:144:110268. doi: 10.1016/j.mehy.2020.110268. Epub 2020 Sep 17.

Authors

Jakub Słupski¹, Wiesław Jerzy Cubała², Natalia Górska², Anita Słupska², Maria Gałuszko-Węgielnik²

Affiliations

¹ Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland. Electronic address: jslupski@gumed.edu.pl.
² Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.

PMID: 33254572
DOI: 10.1016/j.mehy.2020.110268

Abstract

Treatment-resistant depression (TRD) remains one of the major psychiatric challenges worldwide. Search for non-monoaminergic agents, possibly effective in treatment of TRD is of prime importance. One of those agents is ketamine - a dissociative, anesthetic drug exhibiting a fast antidepressant action in patients with TRD. Concurrently, anhedonia appears to be significant symptom domain with far-reaching impact on course of treatment. There is data demonstrating that abnormal copper levels might be associated with symptoms of depression. As there is common denominator in ketamine and copper role in neurotransmission this paper is to explore the associations of blood copper levels and psychometric measures in patients with TRD in course of major depressive disorder (MDD) and bipolar disorder (BP), focusing on anhedonia measured with Snaith-Hamilton Pleasure Scale (SHAPS) score.

Keywords: Anhedonia; Copper; Ketamine; Treatment-resistant depression.

MeSH terms

Copper
Depression / drug therapy
Depressive Disorder, Major* / drug therapy
Depressive Disorder, Treatment-Resistant* / drug therapy
Humans
Ketamine*

Substances

Ketamine
Copper